Logo Lanfrica
  • Accueil
  • Atlas
  • Analyses
  • Documentation
  • Sign in

© 2026 Lanfrica. Tous droits réservés. Tous les droits d'auteur des ressources affichées sur le site Web Lanfrica appartiennent aux détenteurs de droits d'auteur d'origine, sauf indication contraire explicite.

Clinical Trial Designs.

Domaine:

healthcare

Type de record:

paper
Créateur:
CarMuhDomYa
Hôte:avatar

Trial A = Phase Ib clinical trial in The Gambia, West Africa. Trial B = Phase Ib clinical trial in Kilifi, Kenya, East Africa. IM = intramuscular administration. ID = intradermal administration. In Trial A, 10 volunteers were excluded following screening for the following reasons: severe thrombocytopenia, severe proteinuria, spastic deformity of arm and withdrawal of consent (seven individuals). In Trial B, 14 volunteers were excluded following screening for the following reasons: hypertension (two individuals), positive serology for HIV (two individuals), positive Hepatitis B surface antigen (four individuals), participation in a previous malaria vaccine trial (2 individuals), peptic ulcer disease, allergic disease, recruitment complete (one participant).

Visit

figshare.com

Languages

Swahili, Coastal

Tags

PharmacologyImmunologyInfectious DiseasesimmunologyInfectious diseasespharmacology

Licenses

CC BY 4.0

Similaires

INNOVATIVE CLINICAL TRIAL DESIGNSPerformance of different clinical trial designs to evaluate treatments during an epidemicBroad Cross-National Public Support for Accelerated COVID-19 Vaccine Trial Designs

INNOVATIVE CLINICAL TRIAL DESIGNS

Since the middle of the 20th century, randomised controlled trials have provided the strongest level

Performance of different clinical trial designs to evaluate treatments during an epidemic

In the 2013-2016 west Africa outbreak of Ebola Virus Disease (EVD), most of the planned clinical tri

Broad Cross-National Public Support for Accelerated COVID-19 Vaccine Trial Designs

A vaccine for COVID-19 is urgently needed. Several vaccine trial designs may significantly accelerat